Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05787002 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05787002 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 16 participants.
The verdict
NCT05787002, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination with rosuvastatin.
Interventions
- DRUG AZD0780
- DRUG Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-03-09 |
| Est. Completion | 2023-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05787002
The ClinicalTrials.gov registry entry for NCT05787002 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD0780 is the first listed.
NCT05787002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05787002 about?
NCT05787002 is a clinical study titled "A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.". The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination with rosuvastatin.
What is the current status of trial NCT05787002?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-03-09. Estimated completion is 2023-05-15.
What interventions are being tested in trial NCT05787002?
The interventions under investigation include: AZD0780 (DRUG), Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT05787002?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.